Drug intelligence / Profile preview

VAL070-B

Development stage: Unknown
Lead developer: Valbiotis
Administration: Oral

Overview

VAL070-B is a **dietary supplement** formulated as a capsule containing five active plant extracts[1]. It is designed to support lipid metabolism and is being investigated for its potential to lower LDL cholesterol and improve lipid profiles in individuals with moderate hypercholesterolemia and hypertriglyceridemia[1]. The mechanism of action is not specified in detail but, as a combination of plant-derived substances, VAL070-B likely acts through multiple biochemical pathways associated with lipid regulation. The developer and manufacturer are not identified in available sources[1].

Brand names: VAL070-BVAL-070-BVAL 070-B
Other names: VAL070-BVAL-070-BVAL 070-B

Beyond the preview

Go deeper on VAL070-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VAL070-B.

Explore the full profile